Boehringer Ingelheim Pharma GmbH & Co KG Biberach, 88400 Biberach an der Riß, Germany.
Staburo GmbH, 81549 Munich, Germany.
Bioanalysis. 2020 Oct;12(20):1459-1468. doi: 10.4155/bio-2020-0189. Epub 2020 Oct 7.
Guidelines like United States Pharmacopeia 1032 [1] and pharm.Eur. [2] acknowledge that cell-based bioassays are complex methods and thus prone to outliers. However, investigations into root causes of outliers are often inconclusive. We have established a procedure (including quality control and documentation) implemented in a freely available software application which includes not only the experience of the analyst but also information of historical data. This action limit outlier test is unique to our knowledge. Action limit outlier test allows the determination of outliers efficiently which lead to a significant reduction of false positives in comparison with the traditional outlier test ROUT [3] or Rosner [4] alone as shown by our simulated data (58 and 44% reduction of false positives for ROUT and Rosner, respectively).
指南如美国药典 1032 [1] 和欧洲药典 [2] 承认,基于细胞的生物测定是复杂的方法,因此容易出现异常值。然而,对异常值根本原因的调查往往没有定论。我们已经建立了一个程序(包括质量控制和文件记录),并在一个免费提供的软件应用程序中实施,该程序不仅包含分析员的经验,还包含历史数据的信息。据我们所知,这种行动限外试验是独特的。行动限外试验可以有效地确定异常值,与传统的异常值试验 ROUT [3] 或 Rosner [4] 相比,这大大减少了假阳性的数量,我们的模拟数据(ROUT 和 Rosner 的假阳性分别减少了 58%和 44%)证明了这一点。